Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VA/DoD Formulary To Pick Triptan In May; GSK Imitrex Protest Denied

Executive Summary

The Departments of Defense and Veterans Affairs expect to make a formulary decision on the triptan class of migraine products in May

You may also be interested in...



AstraZeneca Zomig on VA/DoD formulary

AstraZeneca's Zomig (zolmitriptan) will be sole triptan on formulary of the Departments of Defense and Veteran Affairs effective July 11. AstraZeneca won the contract by offering a price of $3.20 per tablet, 57% less than Zomig's cheapest price on the Federal Supply Schedule ($44.21 for a six tablet pack of Zomig-ZMT 2.5 mg). The departments had also been considering Pharmacia's - now Ortho-McNeil's - Axert (almotriptan), GlaxoSmithKline's Imitrex (sumatriptan) and Merck's Maxalt (rizatriptan) (1"The Pink Sheet" April 14, 2003, p. 25)...

AstraZeneca Zomig on VA/DoD formulary

AstraZeneca's Zomig (zolmitriptan) will be sole triptan on formulary of the Departments of Defense and Veteran Affairs effective July 11. AstraZeneca won the contract by offering a price of $3.20 per tablet, 57% less than Zomig's cheapest price on the Federal Supply Schedule ($44.21 for a six tablet pack of Zomig-ZMT 2.5 mg). The departments had also been considering Pharmacia's - now Ortho-McNeil's - Axert (almotriptan), GlaxoSmithKline's Imitrex (sumatriptan) and Merck's Maxalt (rizatriptan) (1"The Pink Sheet" April 14, 2003, p. 25)...

Pfizer Relpax To Launch In First Quarter At Maximum Dose Of 40 Mg

Pfizer's Relpax migraine treatment will be launched during the first quarter at a maximum dose of 40 mg

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel